Olink is proud to present a #worldibdday interview to raise awareness about the latest research on prognostic biomarkers in blood to predict disease course and optimize care for pediatric Crohn’s disease patients.
In this exclusive interview, Andres Hurtado-Lorenzo, PhD, Vice President, Translational Research & IBD Ventures, Crohn’s & Colitis Foundation, discusses his research and the adoption of #Olink technology.
In particular, Hurtado-Lorenzo talks about the discovery of 14 proteins in blood, that can predict the likelihood of a child with Crohn’s disease to develop complications within five years after diagnosis.
His ongoing work at the Crohn’s and Colitis Foundation is conducted with key partners such as Genedata, The Foundation for the National Institutes of Health, Olink Proteomics, amongst others.
Link to video interview: